Inhibikase Therapeutics (IKT) director Berman received 108,176 Stock Option (Right to Buy)
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Dennis N Berman (director at Inhibikase Therapeutics Inc., IKT) reported that they received 108,176 Stock Option (Right to Buy) on Jun 30, 2025.
- Reporting person
- Berman Dennis N
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 30, 2025 | Grant or award (A) | Stock Option (Right to Buy)On 108,176 Common Stock1 | +108,176 | - | - | 108,176 direct |
Holdings before and after
- Stock Option (Right to Buy): 0 to 108,176 direct
Footnotes from the filing
- 1. The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Berman report in this IKT Form 4?
Dennis N Berman (director at Inhibikase Therapeutics Inc., IKT) reported that they received 108,176 Stock Option (Right to Buy) on Jun 30, 2025.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for IKT
Earlier insider filings at IKT
- Jul 2, 2025SEC Form 4 filed by Director Bellini Roberto
- Apr 16, 2025SEC Form 4 filed by Chief Financial Officer Mcintyre David
- Feb 25, 2025SEC Form 4 filed by President & Head of R&D Cabell Christopher
- Feb 25, 2025SEC Form 4 filed by Director Aurentz Vincent
- Feb 25, 2025SEC Form 4 filed by Chief Executive Officer Iwicki Mark T
Keep researching IKT
- IKT insider tradesEvery buy and sale reported by Inhibikase Therapeutics Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- IKT financial statementsRevenue, profit, cash flow and balance sheet from Inhibikase Therapeutics Inc.'s SEC filings.
Quantisnow market dataNASDAQ
IKT
Inhibikase Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2020
Get push alerts for IKT
Full IKT profile on Quantisnow Follow IKT and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time